Maynard Um
-
-
-
-
-
-
-
Oculis OCS-01 eye drops fail primary endpoints in diabetic macular edema trials
-
-
-
-
-
-
-
Oculis Holding AG (OCS) PT Raised to $50 at Stifel
-
-
-
-
-
-
-
Needham Starts Oculis Holding AG (OCS) at Buy
-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on Oculis Holding AG (OCS)
-
-
-
-
-
-
-
Oculis Holding (OCS) Appoints Sharon Klier, M.D., M.S., M.P.H. as Chief Development Officer
-
-
-
-
448,126 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

